Dipeptidyl peptidase-4

Results: 120



#Item
71Drug Safety Communication for Saxagliptin

Drug Safety Communication for Saxagliptin

Add to Reading List

Source URL: www.fda.gov

Language: English
72Continuing Education Discussion Guide  A Guide to Emerging Treatments for Type 2 Diabetes: Focus on Incretin Therapies This continuing education discussion guide is part of an educational initiative designed to provide

Continuing Education Discussion Guide A Guide to Emerging Treatments for Type 2 Diabetes: Focus on Incretin Therapies This continuing education discussion guide is part of an educational initiative designed to provide

Add to Reading List

Source URL: www.ashpadvantagemedia.com

Language: English - Date: 2014-02-04 15:23:23
73DIVISION OF BIOEQUIVALENCE REVIEW

DIVISION OF BIOEQUIVALENCE REVIEW

Add to Reading List

Source URL: www.fda.gov

Language: English
74DIVISION OF BIOEQUIVALENCE REVIEW

DIVISION OF BIOEQUIVALENCE REVIEW

Add to Reading List

Source URL: www.fda.gov

Language: English
75COMMONWEALTH of VIRGINIA Department of Medical Assistance Services DRUG UTILIZATION REVIEW PROGRAM Virginia Medicaid Drug Utilization Review (DUR) Board Quarterly Meeting

COMMONWEALTH of VIRGINIA Department of Medical Assistance Services DRUG UTILIZATION REVIEW PROGRAM Virginia Medicaid Drug Utilization Review (DUR) Board Quarterly Meeting

Add to Reading List

Source URL: www.dmas.virginia.gov

Language: English - Date: 2013-03-18 06:50:59
76Nancy A. Thornberry Nancy A. Thornberry is Senior Vice President and Franchise Head, Diabetes and Obesity, for Merck & Co. Inc. In this role, she leads discovery and clinical research in metabolic disorders such as diabe

Nancy A. Thornberry Nancy A. Thornberry is Senior Vice President and Franchise Head, Diabetes and Obesity, for Merck & Co. Inc. In this role, she leads discovery and clinical research in metabolic disorders such as diabe

Add to Reading List

Source URL: www2.kenes.com

Language: English - Date: 2010-05-11 04:44:04
77*JANUVIA™ is the proposed trademark for MK-431 (sitagliptin phosphate)

*JANUVIA™ is the proposed trademark for MK-431 (sitagliptin phosphate)

Add to Reading List

Source URL: www.merck.ca

Language: English - Date: 2014-10-08 00:16:31
78CANADIAN DIABETES ASSOCIATION 2013 CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND MANAGEMENT OF DIABETES IN CANADA DUALITY OF INTEREST DISCLOSURES EXECUTIVE, STEERING & EXPERT COMMITTEES

CANADIAN DIABETES ASSOCIATION 2013 CLINICAL PRACTICE GUIDELINES FOR THE PREVENTION AND MANAGEMENT OF DIABETES IN CANADA DUALITY OF INTEREST DISCLOSURES EXECUTIVE, STEERING & EXPERT COMMITTEES

Add to Reading List

Source URL: guidelines.diabetes.ca

Language: English - Date: 2013-04-24 07:17:09
79Microsoft Word - Dipeptidyl Peptidase-4 _DPP-4_ PDST Summary-Final-V3[removed]doc

Microsoft Word - Dipeptidyl Peptidase-4 _DPP-4_ PDST Summary-Final-V3[removed]doc

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2013-10-03 14:58:53
80Formulary Alternatives for Non-formulary Medications Cost Share Changes Effective July 11, 2012 Non-Formulary (Tier 3) Medications Dipeptidyl Peptidase Inhibitors (DPP4s) Cost share = $25 †

Formulary Alternatives for Non-formulary Medications Cost Share Changes Effective July 11, 2012 Non-Formulary (Tier 3) Medications Dipeptidyl Peptidase Inhibitors (DPP4s) Cost share = $25 †

Add to Reading List

Source URL: www.express-scripts.com

Language: English - Date: 2012-07-12 14:34:08